{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR+Mutation+Positive+Non-small+Cell+Lung+Cancer&page=2",
    "query": {
      "condition": "EGFR Mutation Positive Non-small Cell Lung Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR+Mutation+Positive+Non-small+Cell+Lung+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T03:13:34.209Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02438722",
      "title": "S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Non-Small Cell Lung Carcinoma",
        "Stage IV Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Afatinib Dimaleate",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 174,
      "start_date": "2015-05-07",
      "completion_date": "2026-04-17",
      "has_results": true,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-07-24T03:13:34.209Z",
      "location_count": 638,
      "location_summary": "Fort Smith, Arkansas • Hot Springs, Arkansas • Jonesboro, Arkansas + 406 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Arroyo Grande",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02438722"
    },
    {
      "nct_id": "NCT07538804",
      "title": "A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ANS02",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avistone Biotechnology Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 294,
      "start_date": "2026-07-10",
      "completion_date": "2029-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-07-24T03:13:34.209Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07538804"
    },
    {
      "nct_id": "NCT03778229",
      "title": "Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma"
      ],
      "interventions": [
        {
          "name": "osimertinib",
          "type": "DRUG"
        },
        {
          "name": "savolitinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 367,
      "start_date": "2019-01-09",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-07-24T03:13:34.209Z",
      "location_count": 11,
      "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 8 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03778229"
    },
    {
      "nct_id": "NCT03054038",
      "title": "Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Afatinib",
          "type": "DRUG"
        },
        {
          "name": "Necitumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-07-20",
      "completion_date": "2022-03-23",
      "has_results": false,
      "last_update_posted_date": "2022-04-14",
      "last_synced_at": "2026-07-24T03:13:34.209Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Stanford, California • Nashville, Tennessee",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03054038"
    },
    {
      "nct_id": "NCT04075396",
      "title": "A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Lazertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2019-10-16",
      "completion_date": "2022-11-14",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-07-24T03:13:34.209Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Orlando, Florida • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04075396"
    },
    {
      "nct_id": "NCT02094261",
      "title": "Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "AZD9291",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 210,
      "start_date": "2014-05-20",
      "completion_date": "2023-11-07",
      "has_results": true,
      "last_update_posted_date": "2024-11-06",
      "last_synced_at": "2026-07-24T03:13:34.209Z",
      "location_count": 9,
      "location_summary": "La Jolla, California • Orange, California • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02094261"
    },
    {
      "nct_id": "NCT04862780",
      "title": "(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Respiratory Tract Neoplasms",
        "Neoplasms",
        "Neoplasms by Site",
        "Lung Diseases",
        "Respiratory Tract Disease",
        "Carcinoma, Bronchogenic",
        "Bronchial Neoplasms",
        "Adenocarcinoma",
        "Carcinoma",
        "Neoplasms by Histologic Type",
        "Neoplasms, Nerve Tissue",
        "EGFR T790M",
        "EGFR C797S",
        "EGFR L858R",
        "EGFR Gene Mutation",
        "EGF-R Positive Non-Small Cell Lung Cancer",
        "EGFR Exon 19 Deletion",
        "EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance",
        "EGFR Activating Mutation",
        "Protein Kinase Inhibitors",
        "Antineoplastic Agents",
        "Thoracic Neoplasms"
      ],
      "interventions": [
        {
          "name": "BLU-945",
          "type": "DRUG"
        },
        {
          "name": "osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Blueprint Medicines Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 177,
      "start_date": "2021-06-29",
      "completion_date": "2024-10-07",
      "has_results": false,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-07-24T03:13:34.209Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • Los Angeles, California • Orange, California + 5 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04862780"
    },
    {
      "nct_id": "NCT07285148",
      "title": "A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "EGFR Mutation",
        "Metastatic Lung Cancer",
        "MET Alteration"
      ],
      "interventions": [
        {
          "name": "ANS014004 + PLB1004",
          "type": "DRUG"
        },
        {
          "name": "ANS014004 + Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beijing Pearl Biotechnology Limited Liability Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 253,
      "start_date": "2026-06",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-07-24T03:13:34.209Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07285148"
    },
    {
      "nct_id": "NCT02368990",
      "title": "T790M Mutation Positive 2nd Line STandard of cAre Registry",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-06",
      "completion_date": "2018-06",
      "has_results": false,
      "last_update_posted_date": "2015-07-08",
      "last_synced_at": "2026-07-24T03:13:34.209Z",
      "location_count": 3,
      "location_summary": "Kentucky, Kentucky • Maryland City, Maryland • Langhorne, Pennsylvania",
      "locations": [
        {
          "city": "Kentucky",
          "state": "Kentucky"
        },
        {
          "city": "Maryland City",
          "state": "Maryland"
        },
        {
          "city": "Langhorne",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02368990"
    },
    {
      "nct_id": "NCT04035486",
      "title": "A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed/Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed/Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 587,
      "start_date": "2019-07-02",
      "completion_date": "2026-12-22",
      "has_results": true,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-07-24T03:13:34.209Z",
      "location_count": 23,
      "location_summary": "Bellflower, California • Fullerton, California • La Jolla, California + 19 more",
      "locations": [
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04035486"
    }
  ]
}